Status:

NOT_YET_RECRUITING

Telerehabilitation of Balance Clinical and Economic Decision Support System

Lead Sponsor:

University College, London

Collaborating Sponsors:

National and Kapodistrian University of Athens

University Medical Center Freiburg

Conditions:

Stroke

Mild Cognitive Impairment

Eligibility:

All Genders

40-80 years

Phase:

NA

Brief Summary

This study follows the successfully completed HOLOBalance project which was funded by the EU Horizon 2020 scheme. TheHOLOBalance platform delivers exercises demonstrated via a hologram of the physioth...

Detailed Description

This is an assessor-blinded (researchers assessing the participants will not know what study group participants will be in), randomised (participants will join different study groups randomly) control...

Eligibility Criteria

Inclusion

  • ALL PARTICIPANT
  • Age 40-80 years
  • community dwelling able to walk 500-m independently or with a stick
  • Depression subscale on Hospital Anxiety and Depression Scale \<10/21 (14-item questionnaire)
  • No significant visual impairment (as self-reported by participants)
  • Willing to comply with study procedures, proposed training and testing regime
  • With capacity to consent
  • No acute musculoskeletal or other injuries that would prevent participation in a structured exercise program
  • Is not currently, and has not in the past 8-weeks received any falls/balance/vestibular and/or cognitive rehabilitation.
  • Does not any implanted medical devices or a cardiac pacemaker.
  • Does not have any other co-existing neurological conditions (ie. Multiple sclerosis, Parkinson's disease, neuropathy etc.)
  • Does not have any language or communication deficits impairing their ability to communicate and/or express their thoughts.
  • Has at least one functional hand for grip function and computer use.
  • Fulfilling all of the criteria from one of the below sub-groups
  • STROKE COHORT who will fulfil the additional criteria:
  • Individuals with diagnosis of focal ischaemic or haemorrhagic stroke, as confirmed by a clinical letter.
  • Onset \>/= 3 months prior to study.
  • Montreal Cognitive Assessment (MoCA) score n \>/=23
  • At risk of falls (i.e. Functional Gait Assessment FGA score \</=22/30; FGA is a validated quick balance task assessment) AND/OR having experienced a fall(s) in the last 12 months
  • MCI COHORT who will fulfil the additional criteria:
  • Individuals with new or existing formal diagnosis of MCI, according to the International Classification of Disease 10 (ICD10) , as confirmed by a clinical letter.
  • At risk of falls (FGA \</= 22/30) AND/OR having experienced a fall(s) in the last 12 months.
  • VESTIBULAR COHORT who will fulfill the additional criteria
  • Montreal Cognitive Assessment (MoCA) score n \>/=23
  • Individuals with a diagnosis of a vestibular disorder (peripheral and/or mixed peripheral and central):
  • Peripheral vestibular disorder in which the balance problem lies in the vestibular/balance system within the inner ear.
  • Mixed vestibular disorder in which the balance problem lies in the vestibular/balance system within the inner ear (peripheral) and involving the nerves or neuronal network in the brain/brainstem responsible for balance (central).
  • Chronic dizziness and/or unsteadiness (\>/= 3 months duration) that started at the time or after the vestibular disorder diagnosis.
  • Dizziness handicap inventory (DHI \>34) AND/OR At risk of falls (FGA \</=22/30)
  • LONG COVID-19 COHORT who will fulfill the additional criteria:
  • Montreal Cognitive Assessment (MoCA) score n \>/=23
  • Individuals with laboratory confirmed diagnosis of Covid (\>/=6 months prior to study onset), as confirmed by a clinical letter.
  • Who have been diagnosed with long Covid, as confirmed by a clinical letter.
  • Who have chronic dizziness and/or unsteadiness which started after the Covid illness (self-report by the patient; duration \</=3 months).
  • Dizziness handicap inventory (DHI \>34) AND/OR At risk of falls (FGA \</=22/30)

Exclusion

  • Outside of the stated age bracket
  • Unable to walk independently (even with use of a walking stick)
  • MOCA score \<23
  • Score of 10 or higher on depression subscale of HADS
  • Unwilling to comply with study procedures, proposed training and testing regime
  • No capacity to consent
  • Significant visual impairment or homonymous hemianopia (stroke cohort only) (self-reported)
  • Orthostatic hypotension or uncontrolled hypertension
  • Other neurological problem (e.g. Parkingson's disease, Multiple Sclerosis etc.)
  • Language and communication deficits impairing ability to express thoughts (e.g. Aphasia)
  • Has participated in a clinical drug trial in the past 6 months.
  • Acute musculoskeletal injury that prevents participation in a structured exercise programme (e.g. lower limb fracture).
  • Has an implanted medical device or cardiac pacemaker.
  • Diagnosis of unstable Meniere's or with more than 4 migraines/month at the time of participating in the study
  • Not fulfilling the inclusion criteria for one of the sub-groups (such as criteria for Stroke group, or MCI group, or chronic vestibular disorder group, or long-Covid group), as outlined above.
  • Unable to provide a clinical letter confirming diagnosis.
  • For those with stroke, no visual spatial neglect.

Key Trial Info

Start Date :

September 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 31 2026

Estimated Enrollment :

460 Patients enrolled

Trial Details

Trial ID

NCT06534164

Start Date

September 1 2025

End Date

August 31 2026

Last Update

July 10 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

University Medical Center Freiberg Neurocenter (UKLFR)

Freiberg, Germany

2

National and Kapodistrian University of Athens

Athens, Greece

3

Secretaria Regional de Saúde e Proteção Civil da Região Autónoma da Madeira

Madeirã, Portugal

4

King Chulalongeorn Memorial Hospital (KMCH)

Bangkok, Thailand